Barclays PLC Has $5.11 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Barclays PLC grew its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 9.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 198,756 shares of the company's stock after buying an additional 17,586 shares during the quarter. Barclays PLC owned 0.23% of IDEAYA Biosciences worth $5,108,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. FMR LLC increased its holdings in IDEAYA Biosciences by 2.6% during the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock worth $333,153,000 after purchasing an additional 327,498 shares in the last quarter. Vanguard Group Inc. raised its position in IDEAYA Biosciences by 5.9% in the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock valued at $130,507,000 after buying an additional 282,936 shares during the last quarter. Geode Capital Management LLC raised its position in IDEAYA Biosciences by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock valued at $51,121,000 after buying an additional 43,226 shares during the last quarter. Pictet Asset Management Holding SA lifted its stake in IDEAYA Biosciences by 2.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,941,271 shares of the company's stock valued at $49,891,000 after acquiring an additional 46,931 shares in the last quarter. Finally, Candriam S.C.A. boosted its position in IDEAYA Biosciences by 14.0% during the 4th quarter. Candriam S.C.A. now owns 1,071,825 shares of the company's stock worth $27,546,000 after acquiring an additional 131,385 shares during the last quarter. Institutional investors own 98.29% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on IDYA. Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Stephens restated an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IDEAYA Biosciences has an average rating of "Moderate Buy" and an average target price of $53.58.

IDEAYA Biosciences Trading Up 4.2 %

Shares of IDYA traded up $0.86 during mid-day trading on Friday, reaching $21.33. The company's stock had a trading volume of 470,807 shares, compared to its average volume of 961,041. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42. The business has a 50-day simple moving average of $17.89 and a two-hundred day simple moving average of $23.18. The stock has a market cap of $1.87 billion, a P/E ratio of -6.47 and a beta of 0.51.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The business had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.00 million. Research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.